1. Home
  2. SBFM vs ENSC Comparison

SBFM vs ENSC Comparison

Compare SBFM & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SBFM

Sunshine Biopharma Inc.

N/A

Current Price

$1.20

Market Cap

3.3M

Sector

Health Care

ML Signal

N/A

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

N/A

Current Price

$0.38

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SBFM
ENSC
Founded
2006
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.9M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
SBFM
ENSC
Price
$1.20
$0.38
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
422.8K
21.5M
Earning Date
04-03-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
65.24
EPS
N/A
N/A
Revenue
$36,305,891.00
$5,066,650.00
Revenue This Year
$40.47
$55.01
Revenue Next Year
N/A
$1,033.97
P/E Ratio
N/A
N/A
Revenue Growth
4.11
N/A
52 Week Low
$0.25
$0.23
52 Week High
$3.05
$2.75

Technical Indicators

Market Signals
Indicator
SBFM
ENSC
Relative Strength Index (RSI) 32.50 N/A
Support Level $1.13 N/A
Resistance Level $1.28 N/A
Average True Range (ATR) 0.15 0.00
MACD -0.00 0.00
Stochastic Oscillator 17.02 0.00

Price Performance

Historical Comparison
SBFM
ENSC

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: